GlassScriptPhysician profile
Prashant G Koshy
NPI 1982871695
$18,678.74
in general payments reported to CMS, 2019-2025
70 companies · $3,857 in 2025
The $3,857 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $1,447 · 2021: $2,547 · 2022: $2,304 · 2023: $3,628 · 2024: $3,167 · 2025: $3,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,983 · Travel and Lodging: $2,516 · Education: $93.35 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,982.89 |
| Travel and Lodging | $2,516.28 |
| Education | $93.35 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,242.66 | 2019-2025 | Repatha, Tepezza, Evenity |
| Novo Nordisk INC | $2,081.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biogen, INC. | $1,633.45 | 2023 | |
| Lilly USA, LLC | $1,246.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $913.84 | 2019-2025 | Korlym |
| Mannkind Corporation | $848.28 | 2019-2025 | Afrezza |
| Abbvie INC. | $825.58 | 2019-2025 | |
| Eli Lilly and Company | $784.40 | 2024 | |
| Dexcom, INC. | $668.07 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $601.40 | 2020-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $599.39 | 2019-2022 | |
| Radius Health, INC. | $471.77 | 2019-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $414.42 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $355.87 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $344.19 | 2021-2025 | Recorlev, Gvoke Hypopen, Keveyis |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.32 | 2019-2025 | Jardiance |
| Recordati_rare_diseases_inc. | $281.58 | 2021-2025 | Isturisa, Signifor Lar |
| Companion Medical, INC. | $270.41 | 2019-2020 | |
| Insulet Corporation | $252.10 | 2019-2025 | Omnipod |
| Zealand Pharma US, INC. | $244.41 | 2020-2022 | |
| Ibsa Pharma INC. | $198.91 | 2020-2024 | Tirosint, Licart, Tirosint |
| Tandem Diabetes Care, INC. | $198.73 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $187.82 | 2021-2025 | Cequr Simplicity |
| Valeritas, INC. | $186.95 | 2019 | |
| Amneal Pharmaceuticals LLC | $170.09 | 2019-2025 | Unithroid |
| Intuity Medical INC | $163.16 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Esperion Therapeutics, INC. | $144.01 | 2020-2025 | Nexletol |
| Beta Bionics, INC. | $127.02 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alexion Pharmaceuticals, INC. | $125.15 | 2019-2024 | Strensiq |
| Merck Sharp & Dohme LLC | $115.08 | 2019-2021 | |
| Antares Pharma, INC. | $105.85 | 2020-2022 | |
| Ascensia Diabetes Care US INC. | $102.98 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.00 | 2019-2024 | Cycloset |
| Neurocrine Biosciences, INC. | $87.92 | 2024-2025 | |
| Amarin Pharma, INC. | $86.84 | 2019-2021 | |
| Echosens North America, INC. | $83.99 | 2025 | Fibroscan |
| Amryt Pharma Holdings LTD | $79.68 | 2022-2023 | Mycapssa, Juxtapid |
| Avvisto Therapeutics, LLC | $74.67 | 2025 | Cycloset |
| Madrigal Pharmaceuticals | $68.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $67.02 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $58.02 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Ascendis Pharma Endocrinology INC | $57.45 | 2023-2025 | Yorvipath |
| Horizon Therapeutics Plc | $56.61 | 2020-2023 | Tepezza |
| Curium US LLC | $45.58 | 2022-2024 | Detectnet |
| Ultragenyx Pharmaceutical INC. | $43.34 | 2020-2023 | |
| Sequel Med Tech, LLC | $40.32 | 2025 | Twiist |
| Azurity Pharmaceuticals, INC. | $40.24 | 2024-2025 | Azmiro |
| Averitas Pharma INC. | $38.93 | 2024 | Qutenza |
| Eisai INC. | $37.55 | 2019 | |
| Medtronic USA, INC. | $36.17 | 2020 | |
| Medtronic, INC. | $35.11 | 2021-2025 | Minimed 780g |
| Acella Pharmaceuticals, LLC | $32.26 | 2025 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $29.06 | 2023 | |
| Kyowa Kirin, INC. | $24.13 | 2025 | |
| Coala Life INC | $18.52 | 2021 | |
| Halozyme INC | $18.34 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $17.63 | 2025 | Imcivree |
| Ipsen Biopharmaceuticals, INC | $17.13 | 2021 | |
| Tolmar, INC. | $16.19 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $16.15 | 2025 | Arexvy, Shingrix |
| Medtronic Minimed, INC. | $15.11 | 2019 | |
| Astellas Pharma US INC | $15.09 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $14.17 | 2020 | |
| Roche Diabetes Care, INC. | $13.91 | 2019 | |
| Endo Pharmaceuticals INC. | $13.82 | 2019 | |
| Verity Pharmaceuticals INC. | $13.62 | 2024 | Tlando |
| Grt US Holding, INC. | $13.24 | 2021 | |
| Nevro Corp. | $13.20 | 2023 | Senza |
| Theracosbio, LLC | $8.27 | 2024 | Brenzavvy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,943.92 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prashant Koshy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.